Xometry, Inc. and Subsidiaries
Unaudited Reconciliations of Non-GAAP Financial Measures
(In thousands)
For the Three Months Ended March 31, | ||||||||
2022 | 2021 | |||||||
Adjusted EBITDA: | ||||||||
Net loss | $ | (19,995 | ) | $ | (10,501 | ) | ||
Add (deduct): | ||||||||
Interest expense, interest and dividend income and other expenses | 1,635 | 452 | ||||||
Depreciation and amortization(1) | 1,799 | 734 | ||||||
Income tax benefit | (559 | ) | — | |||||
Amortization of in-place lease asset | 333 | — | ||||||
Stock-based compensation(2) | 3,456 | 505 | ||||||
Revaluation of contingent consideration | 434 | — | ||||||
Transaction costs | 205 | — | ||||||
Income from unconsolidated joint venture | (34 | ) | — | |||||
Adjusted EBITDA | $ | (12,726 | ) | $ | (8,810 | ) |
For the Three Months Ended March 31, | |||||||
2022 | 2021 | ||||||
Non-GAAP Net Loss: | |||||||
Net loss | $ | (19,995 | ) | $ | (10,501 | ) | |
Add (deduct): | |||||||
Depreciation and amortization expense | 1,799 | 734 | |||||
Stock-based compensation | 3,456 | 505 | |||||
Amortization of in-place lease asset | 333 | — | |||||
Amortization of deferred costs on convertible notes | 312 | — | |||||
Unrealized loss on marketable securities | 858 | — | |||||
Revaluation of contingent consideration | 434 | — | |||||
Transaction costs | 205 | — | |||||
Non-GAAP Net Loss | $ | (12,598 | ) | $ | (9,262 | ) | |
Weighted-average number of shares outstanding used to compute Non-GAAP Net Loss per share, basic and diluted | 46,789,585 | 7,924,848 | |||||
Non-GAAP EPS, basic and diluted | $ | (0.27 | ) | $ | (1.17 | ) |